Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

TCI Peptide Therapeutics

TCI Peptide Therapeutics
2009 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Grant LATEST DEAL TYPE
$2.3M LATEST DEAL AMOUNT
5 INVESTORS
Description

Developer of human drugs and intended to be used for treating cachexia. The company's drugs are melanocortin based peptide drugs for treating cardiovascular problems, enabling healthcare practitioners to modify peptides to perform better as drug candidates, with improved half-life, oral activity, and ability to cross the blood-brain barrier.

Formerly Known As
Tensive Controls
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Primary Office
  • 1601 South Providence Road
  • Columbia, MO 65211
  • United States

+1 (573) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore TCI Peptide Therapeutics’s full profile, request a free trial.

TCI Peptide Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 01-Sep-2016 $2.3M 00.00 Completed Generating Revenue
4. Later Stage VC (Series A) 01-Jun-2016 00.00 00.00 Completed Generating Revenue
3. Grant 01-Jan-2014 0000 Completed Generating Revenue
2. Grant 01-Jan-2012 $1.75M Completed Generating Revenue
1. Early Stage VC Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

TCI Peptide Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Centennial Investors Angel Group Minority 000 0000 000000 0
United States Department of Agriculture Government 000 0000 000000 0
National Cancer Institute Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
Missouri Technology Venture Capital Minority 000 0000 000000 0

TCI Peptide Therapeutics Executive Team (2)

Name Title Board
Seat
Contact
Info
Kenneth Gruber Ph.D Chief Executive Officer and President
Michael Callahan Ph.D Vice President